ArticleCancer cell2018
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.
Abstract read
In one paragraph
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 366 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
366citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
366 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies.Molecular cancer · 2024Pooled it
- Efficacy and safety of a combination treatment of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Pooled it
- Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.Cancer immunology, immunotherapy : CII · 2024Trial
- LAG3 checkpoint function and its mechanism of action in therapeutic targeting.Nature reviews. Immunology · 2026Review
- Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review).International journal of oncology · 2026Review
- Resistance to PD-1/PD-L1 blockade: Mechanism and pharmacological strategies.Pharmacological research · 2026Review
- Genetic and biochemical screens identify MGAT1 as a druggable glycosyltransferase target in STK11-mutant lung cancer.The Journal of biological chemistry · 2026Article
- Antibody-Radionuclide Conjugates for Solid Tumors: Multidimensional Strategies from Component Engineering to Synergistic Combination Therapy.International journal of molecular sciences · 2026Review
- Mannooligosaccharides modulate mucin O-glycan-gut microbe interactions and preserve the intestinal barrier in weaned piglets.Journal of animal science and biotechnology · 2026Article
- N-glycans in non-malignant tumor microenvironment cells dampen CAR-T cell function in solid tumors.Journal for immunotherapy of cancer · 2026Article
- Regulation of immune checkpoint molecules in cancer immune evasion and therapy.Nature reviews. Cancer · 2026Review
- Functional role of long non-coding RNA MALAT1 and HOTAIR in lung cancer.Non-coding RNA research · 2026Review
- Profiling protein post-translational modifications in plasma-derived extracellular vesicles as fingerprints for breast cancer subtypes.Genome biology · 2026Article
- Immune implications and therapeutic opportunities of tumor glycosylation.Nature cancer · 2026Review
- Characterizing the Effects of Protein Glycosylation Perturbation on Phosphorylation Signaling.Analytical chemistry · 2026Article
- The mannosyltransferase DPM1 regulates the activity of ER-stress sensor IRE1 in colorectal cancer.Nature communications · 2026Article
- ALG1-mediated PDL1 glycosylation drives macrophage m2 polarization to promote bladder cancer progression.Cell death and differentiation · 2026Article
- TRIM28-mediated SUMOylation of SREBF1 drives PD‑L1 N‑glycosylation and immune evasion in bladder cancer.Cell death & disease · 2026Article
- Durable response to chemoimmunotherapy in a patient with refractory metastatic ovarian clear cell carcinoma: a case report and literature review.The oncologist · 2026Review
- Mechanical force regulates the inhibitory function of PD-1.EMBO reports · 2026Article
306 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
28 authors.
Chia-Wei LiDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Seung-Oe LimDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA.
Ezra M ChungSTCube Pharmaceuticals, Inc., 401 Professional Drive, Suite 250, Gaithersburg, MD 20879, USA.
Yong-Soo KimSTCube Pharmaceuticals, Inc., 401 Professional Drive, Suite 250, Gaithersburg, MD 20879, USA.
Andrew H ParkSTCube Pharmaceuticals, Inc., 401 Professional Drive, Suite 250, Gaithersburg, MD 20879, USA.
Jun YaoDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Jong-Ho ChaDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Tumor Microenvironment Global Core Research Center, College of Pharmacy, Seoul National University, Seoul 151-742, Korea.
Weiya XiaDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Li-Chuan ChanDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Taewan KimDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Shih-Shin ChangDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Heng-Huan LeeDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Chao-Kai ChouDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Yen-Liang LiuDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
Hsin-Chih YehDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
Evan P PerilloDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
Andrew K DunnDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
Chu-Wei KuoCore Facilities for Protein Structural Analysis, Academia Sinica, Taipei 115, Taiwan; Institute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan.
Kay-Hooi KhooInstitute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan.
Jennifer L HsuDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan.
Yun WuDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jung-Mao HsuDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Hirohito YamaguchiDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Tzu-Hsuan HuangDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Aysegul A SahinDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Gabriel N HortobagyiDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Stephen S YooSTCube Pharmaceuticals, Inc., 401 Professional Drive, Suite 250, Gaithersburg, MD 20879, USA.
Mien-Chie HungDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan. Electronic address: mhung@mdanderson.org.
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MComprehensive Training Program in Imaging Science and InformaticsT32EB007507 · NIBIB · UNIVERSITY OF TEXAS AT AUSTIN · PI MARKEY, MIA K, RYLANDER, HENRY GRADY · 2009 to 2024
$2.7MAn integrated imaging tool for probing EGFR subcellular trafficking in real timeR21CA193038 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI DUNN, ANDREW K, YEH, HSIN-CHIH · 2015 to 2017
$625kNCI NIH HHS P30 CA016672NCI NIH HHS R21 CA193038NIBIB NIH HHS T32 EB007507NIEHS NIH HHS 27303C0140
Abstract
Protein glycosylation provides proteomic diversity in regulating protein localization, stability, and activity; it remains largely unknown whether the sugar moiety contributes to immunosuppression. In the study of immune receptor glycosylation, we showed that EGF induces programmed death ligand 1 (PD-L1) and receptor programmed cell death protein 1 (PD-1) interaction, requiring β-1,3-N-acetylglucosaminyl transferase (B3GNT3) expression in triple-negative breast cancer. Downregulation of B3GNT3 enhances cytotoxic T cell-mediated anti-tumor immunity. A monoclonal antibody targeting glycosylated PD-L1 (gPD-L1) blocks PD-L1/PD-1 interaction and promotes PD-L1 internalization and degradation. In addition to immune reactivation, drug-conjugated gPD-L1 antibody induces a potent cell-killing effect as well as a bystander-killing effect on adjacent cancer cells lacking PD-L1 expression without any detectable toxicity. Our work suggests targeting protein glycosylation as a potential strategy to enhance immune checkpoint therapy.
Indexed as
AnimalsAntibodies, MonoclonalCell Line, TumorFemaleHumansLymphocytes, Tumor-InfiltratingMice, Inbred BALB CN-AcetylglucosaminyltransferasesProgrammed Cell Death 1 ReceptorTriple Negative Breast NeoplasmsAntibodies, MonoclonalN-AcetylglucosaminyltransferasesProgrammed Cell Death 1 Receptorantibody-drug conjugateB3GNT3glycosylationimmune checkpoint blockadeimmunosuppressionimmunotherapyPD-1PD-L1receptor internalizationTNBC
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.